Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...
Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced the FDA has granted a new indication for prevention of recurrent ischemic ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced that the FDA has approved its patent foramen ovale occlusion system for patients with a PFO and ...
It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...
FLAGSTAFF, Ariz., March 11, 2021 /CNW/ -- W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England ...
The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...
- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...
The population of patients undergoing patent foramen ovale (PFO) closure in the US doesn’t match those of the clinical trials that formed the basis of the US Food and Drug Administration’s approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results